PharmAbcine Advances Phase 1 Clinical Trial of PMC-403 for nAMD

PharmAbcine, Inc., a South Korea-based clinical-stage developer of medical therapeutics, announced the Safety Review Committee (SRC) approval of single 3-mg dose for the third cohort in phase 1 clinical trial of PMC-403, the company’s candidate treatment for neovascular age-related macular degeneration (nAMD).

The company stated that the phase 1 trial targets patients with nAMB who are no longer responding to anti-VEGF standard therapeutics. With the SRC decision, the trial will advance to the highest single-dose cohort (4 mg) and the first multiple ascending dose cohort (3 mg), potentially providing more advanced data from this phase 1 study.

According to PharmAbcine, PMC-403 is a TIE2-activating antibody with the mechanism of stabilizing pathological and leaky blood vessels. TIE2 receptors, expressed on endothelial cells, are involved in vessel normalization processes such as angiogenesis and intercellular adhesion.